GLG News by Hematologists who Treat Lymphoma

The original plan was to not provide for anesthesia support during the uncomfortable, to say the least, colonoscopys as well as upper endoscopy.

It shares a common mechanism of action with Wyeth's Torisel (mTOR inhibition) and will at least share the market for recurrence after a TK inhibitor fails.

Meta analysis of multiple papers shows an increased risk of dealth in cancer patients receiving Epo products.

IF this agent works it is ORAL and will certainly be more acceptable to patients than the IV Velcade.

Roche Holding may well be leading the way to make gene analysis more cost effective and individualize cancer care by targeting the mutations!!

Merck's HPV vaccine, Gardasil is expected to be approved for boys to extend "herd immunity" and offer more prevention to girls from cervical cancer. This " altruistic" goal comes with benefits for boys: eradication of 90 % of genital warts cases, and possible long term prevention of anal , penile, and...

As expected, FDA gave accelerated approval for Genetech's Avastin in metastatic breast cancer, thus requiring Genentech to do further studies to show survival benefit and confirm the PFS survival. This decision will "officially" introduces Avastin to breast cancer market, where use has been already...

Merck intends to market this viral vaccine to "protect" women from the risk of cervical carcinoma.

Avastin will be used in the therapy of "advanced" metastatic breast cancer, despite controversial data. In a disease with multiple options and a variable course it is virtually impossible to prove improved survival!!

Cephalon's Treanda have shown efficacy in relapsed/refractory indolent NHL and also in CLL, and is expected to get FDA approval for both indications. Cephalon currently has FDA approval for Trisenox for relapsed APL ( a less common form of AML) and is developing Lasteurinib for FLT-3 positive...